production, quality control and biological evaluation of 153sm-tthmp as a possible bone palliation agent

introduction: various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153sm-edtmp. in this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. methods: 153sm-tthmp was prepared starting from 153sm-smcl3, prepared by neutron activation of an enriched 152sm sample (purity >98%), and in-house synthesized tthmp in 1h at 25°c followed by stability tests, partition coefficient determination and biodistribution studies of in wild-type rodents using scarification and spect imaging. results: the radiolabled sm complex was prepared in high radiochemical purity (>99%, itlc) and specific activity of 278 gbq/mmol and demonstrated significant stability at 4, 25 and 37°c (in presence of human serum). initial biodistribution data showed significant bone accumulation of the tracer in 48h. conclusion: 153sm-tthmp can be a potential candidate for bone pain palliation therapy in skeletal metastases, although further biological studies in other mammals is still needed.